J-Pharma Announces First Patient Dosed in Investigator-Initiated Trial Evaluating LAT1 Inhibitor Nanvuranlat in Combination with ICIs in First-Line Biliary Tract Cancer

J Pharma Co., Ltd. and Uniphar Announce Advancement of Nanvuranlat into Phase 3 Clinical Development Following FDA Alignment and Initial Patient Enrollment　Strategic partnership enables direct progression to Phase 3, bypassing additional Phase 2 study, as first patients are randomized in global trial

J-Pharma Announces jRCT Registration of an Investigator-Initiated Trial of Nanvuranlat in Combination with Immune Checkpoint Inhibitors for Biliary Tract Cancer — Toward Combination Therapy with Immune Checkpoint Inhibitors in First-Line Treatment for Biliary Tract Cancer —